These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 28265006)

  • 21. Sym021, a promising anti-PD1 clinical candidate antibody derived from a new chicken antibody discovery platform.
    Gjetting T; Gad M; Fröhlich C; Lindsted T; Melander MC; Bhatia VK; Grandal MM; Dietrich N; Uhlenbrock F; Galler GR; Strandh M; Lantto J; Bouquin T; Horak ID; Kragh M; Pedersen MW; Koefoed K
    MAbs; 2019; 11(4):666-680. PubMed ID: 31046547
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Rationally Designed Peptide Antagonist of the PD-1 Signaling Pathway as an Immunomodulatory Agent for Cancer Therapy.
    Sasikumar PG; Ramachandra RK; Adurthi S; Dhudashiya AA; Vadlamani S; Vemula K; Vunnum S; Satyam LK; Samiulla DS; Subbarao K; Nair R; Shrimali R; Gowda N; Ramachandra M
    Mol Cancer Ther; 2019 Jun; 18(6):1081-1091. PubMed ID: 31015307
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TSR-033, a Novel Therapeutic Antibody Targeting LAG-3, Enhances T-Cell Function and the Activity of PD-1 Blockade
    Ghosh S; Sharma G; Travers J; Kumar S; Choi J; Jun HT; Kehry M; Ramaswamy S; Jenkins D
    Mol Cancer Ther; 2019 Mar; 18(3):632-641. PubMed ID: 30587557
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells.
    John LB; Devaud C; Duong CP; Yong CS; Beavis PA; Haynes NM; Chow MT; Smyth MJ; Kershaw MH; Darcy PK
    Clin Cancer Res; 2013 Oct; 19(20):5636-46. PubMed ID: 23873688
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models.
    Xu C; Zhang Y; Rolfe PA; Hernández VM; Guzman W; Kradjian G; Marelli B; Qin G; Qi J; Wang H; Yu H; Tighe R; Lo KM; English JM; Radvanyi L; Lan Y
    Clin Cancer Res; 2017 Oct; 23(19):5869-5880. PubMed ID: 28679778
    [No Abstract]   [Full Text] [Related]  

  • 26. An optimized protocol for the in vitro generation and functional analysis of human PD1/PD-L1 signal.
    Khedri M; Abnous K; Rafatpanah H; Ramezani M
    J Recept Signal Transduct Res; 2018 Feb; 38(1):31-36. PubMed ID: 29252078
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy.
    Fromm G; de Silva S; Johannes K; Patel A; Hornblower JC; Schreiber TH
    J Immunother Cancer; 2018 Dec; 6(1):149. PubMed ID: 30563566
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.
    Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG
    J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacologic Properties and Preclinical Activity of Sasanlimab, A High-affinity Engineered Anti-Human PD-1 Antibody.
    Al-Khami AA; Youssef S; Abdiche Y; Nguyen H; Chou J; Kimberlin CR; Chin SM; Kamperschroer C; Jessen B; Kern B; Budimir N; Dillon CP; Xu A; Clark JD; Chou J; Kraynov E; Rajpal A; Lin JC; Salek-Ardakani S
    Mol Cancer Ther; 2020 Oct; 19(10):2105-2116. PubMed ID: 32847983
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structural basis of HLX10 PD-1 receptor recognition, a promising anti-PD-1 antibody clinical candidate for cancer immunotherapy.
    Issafras H; Fan S; Tseng CL; Cheng Y; Lin P; Xiao L; Huang YJ; Tu CH; Hsiao YC; Li M; Chen YH; Ho CH; Li O; Wang Y; Chen S; Ji Z; Zhang E; Mao YT; Liu E; Yang S; Jiang W
    PLoS One; 2021; 16(12):e0257972. PubMed ID: 34972111
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma.
    Speranza MC; Passaro C; Ricklefs F; Kasai K; Klein SR; Nakashima H; Kaufmann JK; Ahmed AK; Nowicki MO; Obi P; Bronisz A; Aguilar-Cordova E; Aguilar LK; Guzik BW; Breakefield X; Weissleder R; Freeman GJ; Reardon DA; Wen PY; Chiocca EA; Lawler SE
    Neuro Oncol; 2018 Jan; 20(2):225-235. PubMed ID: 29016938
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A T-cell-dependent antibody response study using a murine surrogate anti-PD-1 monoclonal antibody as an alternative to a non-human primate model.
    Plitnick LM; Hutchins B; Dubey S; Li N; Amin RP; Born S; Mangadu R; Phillips JH; Sriram V; Herzyk DJ
    J Immunotoxicol; 2020 Dec; 17(1):175-185. PubMed ID: 33078980
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High-affinity human programmed death-1 ligand-1 variant promotes redirected T cells to kill tumor cells.
    Liang Z; Li Y; Tian Y; Zhang H; Cai W; Chen A; Chen L; Bao Y; Xiang B; Kan H; Li Y
    Cancer Lett; 2019 Apr; 447():164-173. PubMed ID: 30677447
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel tetravalent bispecific antibody targeting programmed death 1 and tyrosine-protein kinase Met for treatment of gastric cancer.
    Hou W; Yuan Q; Yuan X; Wang Y; Mo W; Wang H; Yu M
    Invest New Drugs; 2019 Oct; 37(5):876-889. PubMed ID: 30511201
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preclinical evaluation of the efficacy, pharmacokinetics and immunogenicity of JS-001, a programmed cell death protein-1 (PD-1) monoclonal antibody.
    Fu J; Wang F; Dong LH; Zhang J; Deng CL; Wang XL; Xie XY; Zhang J; Deng RX; Zhang LB; Wu H; Feng H; Chen B; Song HF
    Acta Pharmacol Sin; 2017 May; 38(5):710-718. PubMed ID: 28317872
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PD-L1/LAG-3 bispecific antibody enhances tumor-specific immunity.
    Jiang H; Ni H; Zhang P; Guo X; Wu M; Shen H; Wang J; Wu W; Wu Z; Ding J; Tang R; Zhou S; Chen B; Yu M; Jing H; Liu J
    Oncoimmunology; 2021; 10(1):1943180. PubMed ID: 34239776
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cancer Cell-Intrinsic PD-1 and Implications in Combinatorial Immunotherapy.
    Yao H; Wang H; Li C; Fang JY; Xu J
    Front Immunol; 2018; 9():1774. PubMed ID: 30105035
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
    Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
    Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of CDX-527: a bispecific antibody combining PD-1 blockade and CD27 costimulation for cancer immunotherapy.
    Vitale LA; He LZ; Thomas LJ; Wasiuk A; O'Neill T; Widger J; Crocker A; Mills-Chen L; Forsberg E; Weidlick J; Patterson C; Hammond RA; Boyer J; Sisson C; Alvarado D; Goldstein J; Marsh HC; Keler T
    Cancer Immunol Immunother; 2020 Oct; 69(10):2125-2137. PubMed ID: 32451681
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preclinical characterization and clinical translation of pharmacodynamic markers for MK-5890: a human CD27 activating antibody for cancer immunotherapy.
    Guelen L; Fischmann TO; Wong J; Mauze S; Guadagnoli M; Bąbała N; Wagenaars J; Juan V; Rosen D; Prosise W; Habraken M; Lodewijks I; Gu D; Stammen-Vogelzangs J; Yu Y; Baker J; Lutje Hulsik D; Driessen-Engels L; Malashock D; Kreijtz J; Bertens A; de Vries E; Bovens A; Bramer A; Zhang Y; Wnek R; Troth S; Chartash E; Dobrenkov K; Sadekova S; van Elsas A; Cheung JK; Fayadat-Dilman L; Borst J; Beebe AM; Van Eenennaam H
    J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36100308
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.